In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383

Pharmaceutical Research

Volumn 32, Issue 12, 2015, Pages 3937-3951

  Ufuk, Ayşe ^a   Somers, Graham ^b   Houston, J Brian ^a   Galetin, Aleksandra ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

alveolar macrophages; lysosomal sequestration; NR8383; respiratory drugs

Indexed keywords

AMMONIUM CHLORIDE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CIPROFLOXACIN; CLARITHROMYCIN; FENOTEROL; FORMOTEROL; IMIPRAMINE; IPRATROPIUM BROMIDE; MONENSIN; NIGERICIN; RESPIRATORY TRACT AGENT; RIFAMPICIN; TERBUTALINE; TIOTROPIUM BROMIDE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; DRUG;

ANIMAL CELL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; LYSOSOMAL SEQUESTRATION; LYSOSOME; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SUBSTRATE CONCENTRATION; CELL LINE; CYTOLOGY; HUMAN; METABOLISM;

ADRENERGIC UPTAKE INHIBITORS; ANTI-INFECTIVE AGENTS; BRONCHODILATOR AGENTS; CELL LINE; CLARITHROMYCIN; HUMANS; IMIPRAMINE; LYSOSOMES; MACROPHAGES, ALVEOLAR; PHARMACEUTICAL PREPARATIONS; TERBUTALINE;

EID: 84946479292     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1753-8     Document Type: Article

References (61)

1. Forbes B, Asgharian B, Dailey LA, Ferguson D, Gerde P, Gumbleton M, et al. Challenges in inhaled product development and opportunities for open innovation. Adv Drug Deliv Rev. 2011;63(1-2):69-87.
2. Gupta V, Thomas C, Ahsan F. Principles and practice of pulmonary drug delivery. In: Narang AS, Mahato RI, editors. Targeted delivery of small and macromolecular drugs. Boca Raton: CRC Press; 2010. p. 371-419.
3. Henning A, Hein S, Schneider M, Bur M, Lehr CM. Pulmonary drug delivery: medicines for inhalation. In: Schäfer-Korting M, editor. Drug delivery. Handbook of experimental pharmacology. 197. Berlin: Springer; 2010. p. 171-92.
4. Taylor G. The absorption and metabolism of xenobiotics in the lung. Adv Drug Deliv Rev. 1990;5(1-2):37-61.
5. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf. 2006;5(4):567-83.
6. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974;23(18):2495-531.
7. Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, et al. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther. 2013;94(1):126-41.
8. Logan R, Funk RS, Axcell E, Krise JP. Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications. Expert Opin Drug Metab Toxicol. 2012;8(8):943-58.
9. Logan R, Kong A, Krise JP. Evaluating the roles of autophagy and lysosomal trafficking defects in intracellular distribution-based drug-drug interactions involving lysosomes. J Pharm Sci. 2013;102(11):4173-80.
10. Chen Y, Walsh RJ, Arriaga EA. Selective determination of the doxorubicin content of individual acidic organelles in impure subcellular fractions. Anal Chem. 2005;77(8):2281-7.
11. Duvvuri M, Krise JP. A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict. Mol Pharm. 2005;2(6):440-8.
12. Togami K, Chono S, Morimoto K. Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in vitro. Biol Pharm Bull. 2013;36(9):1494-9.
13. Funk RS, Krise JP. Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction. Mol Pharm. 2012;9(5):1384-95.
14. Kazmi F, Hensley T, Pope C, Funk RS, Loewen GJ, Buckley DB, et al. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos. 2013;41(4):897-905.
15. Duvvuri M, Gong Y, Chatterji D, Krise JP. Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem. 2004;279(31):32367-72.
16. Lemieux B, Percival MD, Falgueyret JP. Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. Anal Biochem. 2004;327(2):247-51.
17. Helmke RJ, Boyd RL, German VF, Mangos JA. From growth factor dependence to growth factor responsiveness: the genesis of an alveolar macrophage cell line. In Vitro Cell Dev Biol. 1987;23(8):567-74.
18. Helmke RJ, German VF, Mangos JA. A continuous alveolar macrophage cell line: comparisons with freshly derived alveolar macrophages. In Vitro Cell Dev Biol. 1989;25(1):44-8.
19. Onoshita T, Shimizu Y, Yamaya N, Miyazaki M, Yokoyama M, Fujiwara N, et al. The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. Colloids Surf B: Biointerfaces. 2010;76(1):151-7.
20. Togami K, Chono S, Seki T, Morimoto K. Distribution characteristics of telithromycin, a novel ketolide antimicrobial agent applied for treatment of respiratory infection, in lung epithelial lining fluid and alveolar macrophages. Drug Metab Pharmacokinet. 2009;24(5):411-7.
21. McFarland JW, Berger CM, Froshauer SA, Hayashi SF, Hecker SJ, Jaynes BH, et al. Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. J Med Chem. 1997;40(9):1340-6.
22. Ishizaki J, Yokogawa K, Ichimura F, Ohkuma S. Uptake of imipramine in rat liver lysosomes in vitro and its inhibition by basic drugs. J Pharmacol Exp Ther. 2000;294(3):1088-98.
23. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos. 2002;30(12):1497-503.
24. Volgyi G, Ruiz R, Box K, Comer J, Bosch E, Takacs-Novak K. Potentiometric and spectrophotometric pKa determination of water-insoluble compounds: validation study in a new cosolvent system. Anal Chim Acta. 2007;583(2):418-28.
25. Jeppsson AB, Lofdahl CG, Waldeck B, Widmark E. On the predictive value of experiments in vitro in the evaluation of the effect duration of bronchodilator drugs for local administration. Pulm Pharmacol. 1989;2(2):81-5.
26. Takács-Novák K, Józan M, Szász G. Lipophilicity of amphoteric molecules expressed by the true partition coefficient. Int J Pharm. 1995;113(1):47-55.
27. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernas H, Karlen A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem. 1998;41(25):4939-49.
28. Kerns EH, Di L, Petusky S, Kleintop T, Huryn D, McConnell O, et al. Pharmaceutical profiling method for lipophilicity and integrity using liquid chromatography-mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2003;791(1-2):381-8.
29. Assandri A, Perazzi A, Berti M. Studies of binding C3-substitute rifamycins to human and bovine serum albumin. J Antibiot (Tokyo). 1977;30(5):409-15.
30. Agrawal S, Panchagnula R. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos. 2005;26(8):321-34.
31. Ménochet K, Kenworthy KE, Houston JB, Galetin A. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther. 2012;341(1):2-15.
32. Cantrill CA, Skinner RA, Rothwell NJ, Penny JI. An immortalised astrocyte cell line maintains the in vivo phenotype of a primary porcine in vitro blood-brain barrier model. Brain Res. 2012;1479:17-30.
33. Cappell KM, Sinnott R, Taus P, Maxfield K, Scarbrough M, Whitehurst AW. Multiple cancer testis antigens function to support tumor cell mitotic fidelity. Mol Cell Biol. 2012;32(20):4131-40.
34. Daniel WA, Wojcikowski J. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol Toxicol. 1997;80(2):62-8.
35. Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A. 1978;75(7):3327-31.
36. Yabe Y, Galetin A, Houston JB. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos. 2011;39(10):1808-14.
37. Hallifax D, Houston JB. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab Dispos. 2006;34(11):1829-36.
38. Togami K, Chono S, Seki T, Morimoto K. Intracellular pharmacokinetics of telithromycin, a ketolide antibiotic, in alveolar macrophages. J Pharm Pharmacol. 2010;62(1):71-5.
39. Hallifax D, Houston JB. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab Dispos. 2007;35(8):1325-32.
40. Heyneman CA, Reasor MJ. Role of the alveolar macrophage in the induction of pulmonary phospholipidosis by chlorphentermine. II. Drug uptake into cells in vitro. J Pharmacol Exp Ther. 1986;236(1):60-4.
41. Antonini JM, Reasor MJ. Accumulation of amiodarone and desethylamiodarone by rat alveolar macrophages in cell culture. Biochem Pharmacol. 1991;42(Supplement 1):S151-6.
42. Heyneman CA, Reasor MJ. Role of the alveolar macrophage in the induction of pulmonary phospholipidosis by chlorphentermine. I. Drug and phospholipid levels. J Pharmacol Exp Ther. 1986;236(1):55-9.
43. Junod AF. Accumulation of 14 C-imipramine in isolated perfused rat lungs. J Pharmacol Exp Ther. 1972;183(1):182-7.
44. Drew R, Siddik ZH, Mimnaugh EG, Gram TE. Species and dose differences in the accumulation of imipramine by mammalian lungs. Drug Metab Dispos. 1981;9(4):322-6.
45. Frezard F, Garnier-Suillerot A. Permeability of lipid bilayer to anthracycline derivatives. Role of the bilayer composition and of the temperature. Biochim Biophys Acta. 1998;1389(1):13-22.
46. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36(1):164-72.
47. Yamaguchi H, Takeuchi T, Okada M, Kobayashi M, Unno M, Abe T, et al. Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
48. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I. Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010;7(1):187-95.
49. Nakanishi T, Haruta T, Shirasaka Y, Tamai I. Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans. Drug Metab Dispos. 2011;39(1):117-22.
50. Horvath G, Mendes ES, Schmid N, Schmid A, Conner GE, Salathe M, et al. The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. J Allergy Clin Immunol. 2007;120(5):1103-9.
51. Horvath G, Schmid N, Fragoso MA, Schmid A, Conner GE, Salathe M, et al. Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. Am J Respir Cell Mol Biol. 2007;36(1):53-60.
52. Ishizaki J, Yokogawa K, Hirano M, Nakashima E, Sai Y, Ohkuma S, et al. Contribution of lysosomes to the subcellular distribution of basic drugs in the rat liver. Pharm Res. 1996;13(6):902-6.
53. Joshi UM, Kodavanti PR, Coudert B, Dwyer TM, Mehendale HM. Types of interaction of amphiphilic drugs with phospholipid vesicles. J Pharmacol Exp Ther. 1988;246(1):150-7.
54. Fisar Z, Fuksova K, Velenovska M. Binding of imipramine to phospholipid bilayers using radioligand binding assay. Gen Physiol Biophys. 2004;23(1):77-99.
55. Nadanaciva S, Lu S, Gebhard DF, Jessen BA, Pennie WD, Will Y. A high content screening assay for identifying lysosomotropic compounds. Toxicol In Vitro. 2011;25(3):715-23.
56. Fischer H, Atzpodien EA, Csato M, Doessegger L, Lenz B, Schmitt G, et al. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. J Med Chem. 2012;55(1):126-39.
57. Higgins JW, Ke AB, Zamek-Gliszczynski MJ. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. Drug Metab Dispos. 2014;42(11):1780-4.
58. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos. 2012;40(5):1007-17.
59. Poirier A, Funk C, Scherrmann JM, Lave T. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm. 2009;6(6):1716-33.
60. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328(2):652-62.
61. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, et al. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther. 2013;94(1):64-79.